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Clinical Significance
• There is wide variety of registries on atrial fibrillation with evident differences in design and methodology.
• Registry data demonstrate that despite gradual improvement in anticoagulation rates worldwide, there are apparent regional differences and gaps in stroke prevention with approximately a third of atrial fibrillation patients not treated in accord with guidelines.
• Remote mortality of atrial fibrillation patients is relatively high, while guidelineadherent antithrombotic therapy significantly reduces thromboembolism and improves survival.
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Over the last decade our knowledge of atrial fibrillation has substantially improved, mainly due to better understanding of epidemiology and pathophysiology of stroke and thromboembolism. As a consequence, new risk factors for stroke have been identified and our procedure for assessment of patients at risk has changed; formerly there was a tenacious search for patients at high thromboembolic risk, whereas now there is an effort to identify those individuals who are at truly low risk of stroke and do not need any antithrombotic treatment, so that stroke prevention can be focused on those with ≥1 stroke risk factors [1] [2] [3] [4] [5] [6] .
These changes coincided with the introduction of non-Vitamin K Antagonist oral anticoagulants (NOACs), which offer greater efficacy, safety and convenience compared with the Vitamin K Antagonists (VKAs, e.g. warfarin) [7] [8] [9] [10] .
Recently, several national and worldwide registries were initiated, predominantly to assess whether daily clinical practice is in accord with atrial fibrillation guidelines and to collect data on treatment with new drugs. Design and methodology of those registries vary substantially and have evolved over the last decade. This review provides an overview of past and current atrial fibrillation registries with respect to treatment patterns for stroke prophylaxis as well as aims to inform clinicians on the interpretation of results and limitations that may be inherent in different registry designs.
Methods
We searched PubMed, Science Direct and Cochrane Library databases for studies that reported on atrial fibrillation and stroke thromboprophylaxis. Multiple queries using following keywords were performed on July 1, 2016: ('atrial fibrillation' AND 'registry') AND ('stroke prevention' OR 'antithrombotic treatment' OR 'oral anticoagulation'). We screened titles and abstracts for relevance to the topic. Articles of selected titles and abstracts were then reviewed for inclusion.
Purpose and Design of Various Observational Studies
There is considerable variety in registry design (Tables 1-3) . National registries, like e.g.
Swedish and Danish National Patient Registries, are 'real time' databases of the whole country population, where every patient is enrolled, every prescribed drug recorded, followup of patients is counted in years and vital status along with cause of death can be routinely M A N U S C R I P T A C C E P T E D intended not only to gather data, but also to provide a wide spectrum of health care sites with support to improve guideline adherence, arrhythmia management, and finally treatment outcomes 22 . There are also registries that record only baseline cross-sectional data 23, 24 ; though most have follow-up analyses. Registries have varying strategies to ensure data quality with some implementing rigorous standards, such as on site monitoring, extensive edit checks, frequent manual data reviews and periodic quality review of aggregate data. Others may not include such checks or make no mention of whether such standards were implemented, thus the measures taken to ensure data integrity should be considered when interpreting data. 
of patients with CHA 2 DS 2 -VASc=0, whereas only 66.7% of those with CHA 2 DS 2 -VASc=9 were anticoagulated 38 .
Guideline-adherent antithrombotic therapy was low at 61%, with 17.3% of patients being undertreated and 21.7% overtreated 40 . Importantly, antithrombotic management which was in line with the 2012 ESC guidelines, was associated with significantly better outcomes (all cause death/thromboembolic event of 9.0%), whereas the corresponding numbers for underand overtreatment were 14.3% and 13.9% respectively 40 .
One-year outcomes of EHS and EORP-AF Pilot Registry were strikingly similar. Mortality rates were 5.3% vs 5.7% respectively and the cause of death was cardiovascular in 67% vs 70%, respectively 41, 42 . Death rates were highest in both registries in persistent/permanent atrial fibrillation, but also in a first-detected arrhythmia. However, one year stroke rates were higher in EHS than in EORP-AF (1.8% vs 0.6% respectively) 41,42 . Of note, in the EHS anticoagulation was discontinued in 45% of patients with no reoccurrence of arrhythmia and in 63% patients who were considered cured 42 . This is of importance, as undertreatment resulted in a 2-fold increase in thromboembolic events, compared with guideline-adherent management 30 .
North American Perspective
OAC was low in the US outpatient registry sponsored by the American College of Cardiology . 
AF Registries Centred on Asia
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Industry-Sponsored Registries
Suboptimal adherence to guidelines and regional differences in treatment patterns have been also observed in industry-sponsored registries.
GLORIA-AF is one of the largest, currently ongoing registries, that was initiated in 2011, and aims to enroll up to 56,000 patients from nearly 50 countries worldwide 17 . It has an innovative inception cohort design consisting of 3 overlapping phases ( Figure 1 and Tables 2-3 ). The first phase of the study includes a period before NOAC introduction, the second phase begins immediately following approval of NOACs in a given country, and the third phase starts following propensity score comparisons in a region, between patient populations on VKA vs NOACs, to ensure baseline characteristics of those patients can be reasonably compared 17 . Such a registry design allows collection of data where there is dynamically changing clinical practice and available treatment methods with a reduced study bias. It also allows description of the pre-NOAC era 58 and the early period immediately following first NOAC approval 59 , and can further inform about changing prescription patterns as the landscape of NOAC availability changes. It also implements a 'new user' design, which only includes incident cases of atrial fibrillation (diagnosed within the previous 3 months) to limit the potential for confounding factors such as disease co-morbidity 17, 59 .
Report from phase I (between May 2011 and January 2013) of GLORIA-AF showed OAC at 64.1% and 20.3% in Europe and China, respectively 58 . Though results of phase II (between November 2011 and February 2014) comprising over 10,000 patients were still showing regional differences in antithrombotic treatment patterns, the overall OAC uptake substantially increased to 80% (32.3% VKA and 47.7% NOAC) 59 . The highest OAC rates were observed in Europe at 90.2%, followed by 78.2% in North America and 57.4% in Asia M A N U S C R I P T A C C E P T E D Importantly, the two-year all-cause mortality was 3.83 per 100 person-years and was far more frequent than the incidence of stroke or major bleeding (1.25 and 0.70 per 100 person-years, respectively) 62 . The cause of death was cardiovascular in 40.5% of cases and congestive heart failure with sudden cardiac death were responsible for 10.8% and 7.5% of deaths, respectively 62 .
Comparing the Registries
Direct comparison of registries is not straightforward (Tables 1-3 ). There are different inclusion criteria for atrial fibrillation and its duration. For example, in GLORIA-AF and GARFIELD-AF only new onset arrhythmia (<6 weeks in GARFIELD-AF and <3 months in GLORIA-AF) is permitted, while it is <12 months in PREFER-AF and arrhythmia detected by implantable pacemaker/cardioverter-defibrillator is also allowed 17,18,63 .
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10 risk factor in CHA 2 DS 2 -VASc scale, while GARFIELD-AF does not use any stroke risk scales, enrolling patients with at least one risk factor at the discretion of physicians. PREFER-AF or ORBIT-AF enroll 'all comers', regardless of presence or absence of stroke risk factors 17,18,63 . To omit the influence of previous anticoagulation, GLORIA-AF excluded patients with a history of VKA therapy ≥60 days, whereas the rest of the registries are recruiting patients irrespective of previous or current OAC (Table 3) .
Comparison of anticoagulation rates requires consideration of several factors, the most important of which seem to be the calendar year and time period of data collection. Indeed, OAC uptake is gradually, but constantly increasing worldwide and thus more recent reports show higher OAC rates 59, 61 . However, registry design, regional contribution and availability of approved medications are also important (Table 3) 17, 59 . Impact of site and setting may also play a role as e.g. registries from the region of Asia/Pacific may report lower OAC rates 59, 60 .
The proportions of in-and outpatients, academic institutions, participating physician specialties, patients of different ethnicities, different health care providers, and funding of the registries need to be also considered 59, 60, 63, 64 . Indeed, in several registries, OAC was high where cardiologists were responsible for treatment 25, 26, 38, 41, 59, 65 . When a broader spectrum of care settings was analyzed, including patients treated by other specialists, then the overall OAC was lower 60, 66 .
Finally, there are various atrial fibrillation guidelines issued by different organizations, which may differ with respect to stroke prevention recommendations 67 . American guidelines for example permit the use of aspirin or even no antithrombotic treatment in some patients (e.g.
with CHA 2 DS 2 -VASc=1) 36 .
Quo Vadis? Has Clinical Practice Changed?
Since the EHS over a decade ago 
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Possible reasons for an increase in OAC prescription over the last years may be increasing availability of NOACs, but also new guidelines and increased awareness of atrial fibrillation and stroke burden. This is also reflected by the falling number of patients being prescribed aspirin or those untreated 25, 40 . Contraindications (approximately 10% of patients) and refusal to accept OAC are also important as these are often subjective and change over time 72 . These patients are generally older and more frail, with multiple comorbidities, but also at higher risk of stroke. In the ORBIT-AF registry, the most frequent reasons for warfarin forgoing were physician preference/choice (47.7%) and patient preference/refusal (21.1%) 60, 73 .
Conclusions
Though differences amongst registries on atrial fibrillation are evident, their main findings are similar and consistent thus giving us a very comprehensive insight into current clinical practice. Despite a gradual increase in anticoagulation rates worldwide, gaps in stroke prevention are still apparent, while guideline-adherent thromboprophylaxis improves outcomes 30, 40 . Long-term mortality of atrial fibrillation patients is relatively high, exceeding both ischemic and bleeding events, mainly due to comorbid disease 41,42,62 . • There is wide variety of registries on atrial fibrillation with evident differences in design and methodology.
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• Remote mortality of atrial fibrillation patients is relatively high, while guideline-adherent antithrombotic therapy significantly reduces thromboembolism and improves survival.
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Highlights
• This paper reviews past and currently ongoing atrial fibrillation (AF)
registries.
• Main focus is on antithrombotic treatment patterns for stroke prevention.
• Design, strengths and limitations of various AF registries are discussed.
• Up-to-date situation on AF thromboprohylaxis worldwide is provided.
• Gaps in AF guideline-adherent antithrombotic therapy were identified and described.
